Search research articles
Contact Us
Filters
Showing results (1-10 of 87) with videos related to
Page
of 9
Sort By:
Medecine Sciences : M/S
|
October 10, 2017
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]
Stéphane Champiat, Jean-Charles Soria
Bulletin Du Cancer
|
January 23, 2015
[Breaking immune tolerance in cancer]
Mélanie Desbois, Stéphane Champiat, Nathalie Chaput
Journal of Geriatric Oncology
|
June 20, 2016
The development of immunotherapy in older adults: New treatments, new toxicities?
Carole Helissey, Cécile Vicier, Stéphane Champiat
European Journal of Cancer (Oxford, England : 1990)
|
January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progress
Roch Houot, Aurélien Marabelle, Stéphane Champiat
The New England Journal of Medicine
|
January 20, 2017
Myocarditis with Immune Checkpoint Blockade
Stéphane Ederhy, Anne-Laure Voisin, Stéphane Champiat
Bulletin Du Cancer
|
June 6, 2013
[Immune-checkpoints: the new anti-cancer immunotherapies]
Ecaterina Ileana, Stéphane Champiat, Jean-Charles Soria
La Revue Du Praticien
|
April 16, 2019
[Management of adverse events associated with cancer immunotherapy]
Stéphane Champiat, Jean-Marie Michot, Olivier Lambotte
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 21, 2019
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Roberto Ferrara, Caroline Caramella, Benjamin Besse, et al.
Oncotargets and Therapy
|
May 2, 2019
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, et al.
La Revue Du Praticien
|
June 23, 2021
[Management of adverse events associated with cancer immunotherapy]
Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 87) with videos related to
Sort By:
Page
of 9
Medecine Sciences : M/S
|
October 10, 2017
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]
Stéphane Champiat, Jean-Charles Soria
Bulletin Du Cancer
|
January 23, 2015
[Breaking immune tolerance in cancer]
Mélanie Desbois, Stéphane Champiat, Nathalie Chaput
Journal of Geriatric Oncology
|
June 20, 2016
The development of immunotherapy in older adults: New treatments, new toxicities?
Carole Helissey, Cécile Vicier, Stéphane Champiat
European Journal of Cancer (Oxford, England : 1990)
|
January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progress
Roch Houot, Aurélien Marabelle, Stéphane Champiat
The New England Journal of Medicine
|
January 20, 2017
Myocarditis with Immune Checkpoint Blockade
Stéphane Ederhy, Anne-Laure Voisin, Stéphane Champiat
Bulletin Du Cancer
|
June 6, 2013
[Immune-checkpoints: the new anti-cancer immunotherapies]
Ecaterina Ileana, Stéphane Champiat, Jean-Charles Soria
La Revue Du Praticien
|
April 16, 2019
[Management of adverse events associated with cancer immunotherapy]
Stéphane Champiat, Jean-Marie Michot, Olivier Lambotte
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 21, 2019
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Roberto Ferrara, Caroline Caramella, Benjamin Besse, et al.
Oncotargets and Therapy
|
May 2, 2019
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, et al.
La Revue Du Praticien
|
June 23, 2021
[Management of adverse events associated with cancer immunotherapy]
Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Page
of 9